Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Kyorin Pharmaceutical Co.,Ltd

Clinicaltrial registered5 Nov 2026

Kyorin Pharmaceutical Co.,Ltd

5 Nov 2026: Trial registered · A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval in Healthy Participants. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
5 Nov 2026
Title
A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval in Healthy Participants
Conditions
Healthy Participants
Phase
Phase 1
Study Type
Interventional
Status
Recruiting
Countries
Canada
Country
Canada
Reference
NCT07919314
Location
Canada
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Kyorin Pharmaceutical Co.,Ltd

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Canada

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.